Vaxcyte (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 10,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.89, for a total value of $538,900.00. Following the transaction, the chief financial officer owned 105,176 shares in the company, valued at approximately $5,667,934.64. This trade represents a 8.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, July 6th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00.
• On Thursday, June 18th, Andrew Guggenhime sold 10,000 shares of Vaxcyte stock. The shares were sold at an average price of $53.00, for a total transaction of $530,000.00.

Vaxcyte Trading Up 2.2%

PCVX traded up $1.23 during trading on Wednesday, hitting $55.92. The stock had a trading volume of 886,273 shares, compared to its average volume of 1,429,150. The firm has a market cap of $8.07 billion, a PE ratio of -8.13 and a beta of 1.23. Vaxcyte, Inc. has a 12 month low of $29.08 and a 12 month high of $65.00. The company has a 50 day simple moving average of $53.47 and a 200-day simple moving average of $55.05.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.06) by $0.09. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Finally, Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Hold” and a consensus price target of $86.00.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently made changes to their positions in PCVX. Handelsbanken Fonder AB grew its position in Vaxcyte by 20.8% during the second quarter. Handelsbanken Fonder AB now owns 49,400 shares of the company’s stock worth $2,872,000 after buying an additional 8,500 shares in the last quarter. Empowered Funds LLC raised its holdings in Vaxcyte by 111.8% in the 1st quarter. Empowered Funds LLC now owns 9,692 shares of the company’s stock valued at $563,000 after acquiring an additional 5,116 shares in the last quarter. Seven Fleet Capital Management LP lifted its position in shares of Vaxcyte by 406.4% in the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company’s stock worth $7,464,000 after acquiring an additional 103,085 shares during the period. DV Trading LLC acquired a new stake in shares of Vaxcyte during the 1st quarter worth approximately $1,162,000. Finally, Bank of America Corp DE grew its holdings in shares of Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after purchasing an additional 515,209 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.